Eidogen-Sertanty's Target Informatics Platform™ (TIP™) is the world's first structural informatics system and knowledgebase that enables researchers with the ability to interrogate the druggable genome from a structural perspective. TIP™ amplifies the rapidly expanding body of experimental protein structure information and transforms structure-based drug discovery from a low-throughput, data scarce discipline into a high-throughput, data rich science. Designed to help bridge the knowledge gap between bioinformatics and cheminformatics, TIP™ supplies drug discovery researchers with a knowledgebase of information that is both distinct from and highly complementary to information furnished by existing bio- and cheminformatics platforms. TIP's seamless integration of structural data management technology with unique target-to-lead calculation and analysis capabilities enhances all stages of the discovery pipeline.

• TIP Content, Curation & Calculation Engine
• TIP Web Portal

• Eidogen Visualization Environment™ (EVE™)
• Multiple Ways to Leverage TIP

TIP's™ Value to Drug Discovery

• Increase the Efficiency of Lead Discovery and Optimization
  • TIP™ enables chemists to derive an unprecedented level of relevant structural information that can be used to integrate rational and hypothesis-driven analyses into current and future lead discovery and optimization projects:
    • Quickly Identify Potential Leads using novel correlations between new annotated binding sites and sites with known ligands.
    • Improve Drug Selectivity with easy-to-use comparative binding site analysis and visualization tools.
    • Survey the Landscape of Target-Ligand Interactions across an entire family of drug targets, maximizing the knowledge that can be derived from structures with docked or co-crystallized ligands.
      
      
• Discover New Opportunities for Validated Targets and Compounds
  • TIP™ furnishes reliable information about new opportunities and applications that can otherwise only be discovered via costly and time-consuming experimental efforts:
    • Discover and Evaluate Novel Binding Sites in previously validated and proven drug targets.
    • Develop Lead Hopping and Target Hopping strategies using pre-calculated similarities at the binding site, target-ligand interaction fingerprint, or ligand levels.
      
      
• Increase the Overall Quality of the Target Portfolio
  • TIP™ supplies druggability and selectivity information to support highly informed target selection and prioritization decisions:
    • Quickly Understand Target Druggability based on a detailed annotation of available small molecule binding sites and understanding of gene family-wide similarity for targets of interest.
    • Derive Maximum Value from the Distribution of Target Knowledge utilizing TIP's centralized system for managing all structure, binding site annotation, selectivity, and co-crystallized and docked ligand interactions for all targets of interest, across all members of a project team.
      
      

• Target Prioritization Applications
  • Target Druggability Assessment
    • Binding Site Property Analysis
    • Binding Site Selectivity Analysis
    • SNP structural mapping and analysis
    • Drug Resistance Mutation Analysis
    • Drug Target Clustering
  • Animal Model Suitability Analysis
  • Broad Spectrum Anti-Infective Target Analysis
    
    
• Lead Discovery Applications
  • Novel Lead Fragment & Scaffold Discovery
  • Binding Site Property Analysis & HTS Library Selection
  • Structure-Based Library Design
  • VLS Binding Mode Analysis
    
    
• Lead Optimization Applications
  • Structure-Based Ligand Affinity Optimization
  • Structure-Based Selectivity Optimization
  • Structure-Based Broad Spectrum Anti-Infective Optimization
  • Structure-Based Co-Inhibitor Affinity Optimization
  • "Off-Target" Discovery and Analysis
  • "Off-Target" Assay Panel Design
    
    
• Opportunity Discovery
  • Novel Drug Rescue Opportunities
    • Due to Drug-Induced Mutations
    • Due to Poor Selectivity within a Family
    • Due to "Off-Target" Interactions
  • Novel Drug Redesign Opportunities
  • Novel Drug Binding Site Opportunities
  • Novel Co-Inhibition Opportunities
  • Novel Anti-infective opportunities